Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test

Richard Chen, MD, President & Chief Medical Officer of Personalis

“At Personalis, we have continued to push the boundaries of what’s possible with MRD testing, beginning with ultrasensitive detection and now with variant tracking.”

Richard Chen, MD, President & Chief Medical Officer of Personalis

“Real-Time Variant Tracker was developed in recognition that clinically informative variants, including resistance mutations, can emerge during MRD monitoring.”

Leo Shunyakov, M.D., Medical oncologist and hematologist at Central Care Cancer Center

“The ultrasensitivity of NeXT Personal allows us to detect very low levels of ctDNA, which can be particularly important when we’re monitoring patients whose disease may be difficult to assess through conventional measures alone.”

Leo Shunyakov, M.D., Medical oncologist and hematologist at Central Care Cancer Center

“I see opportunities for highly sensitive ctDNA testing in settings including historically challenging tumor types such as earlier-stage breast and lung cancers.”

Leo Shunyakov, M.D., Medical oncologist and hematologist at Central Care Cancer Center

“And as we follow patients over time, we’re not only asking whether disease is present, but also how the biology of the cancer may be changing. Real-Time Variant Tracker follows those changes over the course of NeXT Personal testing.”